Esperion Therapeutics | ESPR - Selling And Administration Expenses


Esperion Therapeutics reported $39.42M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Amarin USD 18.97M 1.03M Dec/2025
Amgen USD 1.58B 354M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Cipla INR 13.25B 101.8M Dec/2025
CSL USD 1.23B 498M Dec/2025
Cytokinetics USD 91.72M 67.02M Dec/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Esperion Therapeutics USD 39.42M 456K Dec/2025
Geron USD 41.67M 2.67M Dec/2025
Grifols EUR 320.45M 12.65M Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Ionis Pharmaceuticals USD 151M 21M Mar/2026
Merck USD 2.67B 180M Mar/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Moderna USD 173M 135M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Sanofi EUR 2.33B 419M Mar/2026
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
United Therapeutics USD 190.6M 38.6M Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024